Cat. No.: DIA-0231304
Product Information | |
---|---|
CAS No. | 72-48-0 |
Synonyms | Anthraquinonic |
Formula | C14H8O4 |
Molecular Weight | 240.21 |
SMILES | OC1=C(O)C2=C(C=C1)C(=O)C3=CC=CC=C3C2=O |
Target | CYP2C19, CYP3A4 and CYP3A5. |
Product Description | Alizarin strongly inhibits P450 isoform CYP1A1, CYP1A2 and CYP1B1 with IC50 of 6.2 μM, 10.0 μM and 2.7 μM, respectively weakly inhibits CYP2A6 and CYP2E1, and does not inhibit CYP2C19, CYP3A4 and CYP3A5. |
Format & Storage | |
---|---|
Purity | > 99% |
Shipping | Shipped on dry ice. |
Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.